Ignite Creation Date:
2024-05-05 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00099255
Status:
COMPLETED
Last Update Posted:
2014-12-18
First Post:
2004-12-10
Brief Title:
Study of SGN-30 Anti-CD30 mAb in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
Sponsor:
Seagen Inc
Organization:
Seagen Inc
Study Overview
Official Title:
A Phase II Multi-Dose Study of SGN-30 Anti-CD30 mAb in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma Large Cell Transformation of Mycosis Fungoides and Lymphomatoid Papulosis
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This multi-center phase II study will be conducted to define the toxicity profile and antitumor activity of SGN-30 in patients with pcALCL and other closely related lymphoproliferative disorders
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None